^
Association details:
| Biomarker: | MET exon 14 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tabrecta (capmatinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Excerpt:
TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
Source:
Title:
Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis
Published date:
08/31/2022
Excerpt:
...a case of a 65-year-old woman who was diagnosed with metastatic lung adenocarcinoma….Plasma genotyping revealed that the tumor harbored a MET exon 14 skipping mutation, and we started capmatinib, a selective MET inhibitor. The CNS lesions markedly decreased and the performance status of the patient dramatically improved.
DOI:
https://doi.org/10.2147/OTT.S382722
Title:
Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in A Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report
Published date:
12/21/2020
Excerpt:
A 75-year-old Japanese female never-smoker was presented with a small lung 66 nodule in the right upper lobe...sequencing analysis of the 79 biopsy specimens with FoundationOne®CDx and it revealed a MET exon 14 skipping mutation...She was treated with oral capmatinib at a dose of 400 mg twice daily. However, after the treatment for 6 days, mild cough and dyspnea developed and a chest X ray and CT scan showed widespread ground-glass opacities in both lungs...
DOI:
https://doi.org/10.1016/j.jtocrr.2021.100271
Test:
